Catalent Inc (CTLT) Stock Fundamental Analysis
NYSE:CTLT - US1488061029 - Common Stock
63.48 USD
0 (0%)
63.5 USD
+0.02 (+0.03%)
We assign a fundamental rating of 3 out of 10 to CTLT. CTLT was compared to 195 industry peers in the Pharmaceuticals industry. CTLT may be in some trouble as it scores bad on both profitability and health. CTLT is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CTLT was profitable.
CTLT had a positive operating cash flow in the past year.
In multiple years CTLT reported negative net income over the last 5 years.
Each year in the past 5 years CTLT had a positive operating cash flow.
1.2 Ratios
CTLT has a better Return On Assets (-4.25%) than 78.01% of its industry peers.
CTLT has a Return On Equity of -11.66%. This is in the better half of the industry: CTLT outperforms 75.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.25% | ||
| ROE | -11.66% | ||
| ROIC | N/A |
ROA(3y)-2.82%
ROA(5y)-0.09%
ROE(3y)-8.14%
ROE(5y)-1.42%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 21.82%, CTLT is in line with its industry, outperforming 51.83% of the companies in the same industry.
CTLT's Gross Margin has declined in the last couple of years.
CTLT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 21.82% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.68%
GM growth 5Y-7.41%
2. Health
2.1 Basic Checks
CTLT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CTLT has been increased compared to 1 year ago.
The number of shares outstanding for CTLT has been increased compared to 5 years ago.
The debt/assets ratio for CTLT is higher compared to a year ago.
2.2 Solvency
CTLT has an Altman-Z score of 1.62. This is a bad value and indicates that CTLT is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.62, CTLT is in the better half of the industry, outperforming 64.92% of the companies in the same industry.
CTLT has a debt to FCF ratio of 49.84. This is a negative value and a sign of low solvency as CTLT would need 49.84 years to pay back of all of its debts.
The Debt to FCF ratio of CTLT (49.84) is better than 78.01% of its industry peers.
CTLT has a Debt/Equity ratio of 1.38. This is a high value indicating a heavy dependency on external financing.
CTLT's Debt to Equity ratio of 1.38 is on the low side compared to the rest of the industry. CTLT is outperformed by 74.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.38 | ||
| Debt/FCF | 49.84 | ||
| Altman-Z | 1.62 |
ROIC/WACCN/A
WACC9.31%
2.3 Liquidity
A Current Ratio of 2.51 indicates that CTLT has no problem at all paying its short term obligations.
CTLT's Current ratio of 2.51 is in line compared to the rest of the industry. CTLT outperforms 46.07% of its industry peers.
CTLT has a Quick Ratio of 1.93. This is a normal value and indicates that CTLT is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.93, CTLT perfoms like the industry average, outperforming 44.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.51 | ||
| Quick Ratio | 1.93 |
3. Growth
3.1 Past
CTLT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -61.40%.
CTLT shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -33.48% yearly.
The Revenue has been growing slightly by 4.71% in the past year.
The Revenue has been growing by 11.71% on average over the past years. This is quite good.
EPS 1Y (TTM)-61.4%
EPS 3Y-56.51%
EPS 5Y-33.48%
EPS Q2Q%-30%
Revenue 1Y (TTM)4.71%
Revenue growth 3Y3.1%
Revenue growth 5Y11.71%
Sales Q2Q%4.18%
3.2 Future
CTLT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 73.38% yearly.
CTLT is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.44% yearly.
EPS Next Y350.55%
EPS Next 2Y148.11%
EPS Next 3Y113.64%
EPS Next 5Y73.38%
Revenue Next Year8.33%
Revenue Next 2Y8.2%
Revenue Next 3Y8.33%
Revenue Next 5Y7.44%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CTLT is valuated quite expensively with a Price/Earnings ratio of 288.55.
Based on the Price/Earnings ratio, CTLT is valued a bit cheaper than the industry average as 78.01% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.90, CTLT is valued quite expensively.
With a Price/Forward Earnings ratio of 41.25, CTLT can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, CTLT is valued a bit cheaper than 76.44% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.52, CTLT is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 288.55 | ||
| Fwd PE | 41.25 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CTLT indicates a somewhat cheap valuation: CTLT is cheaper than 76.96% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, CTLT is valued a bit cheaper than the industry average as 78.53% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 116.39 | ||
| EV/EBITDA | 36.47 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CTLT's earnings are expected to grow with 113.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.82
PEG (5Y)N/A
EPS Next 2Y148.11%
EPS Next 3Y113.64%
5. Dividend
5.1 Amount
No dividends for CTLT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
63.48
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners92.2%
Inst Owner Change-8.79%
Ins Owners0.48%
Ins Owner Change0%
Market Cap11.52B
Analysts52.86
Price Target64.77 (2.03%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-149.78%
Min EPS beat(2)-336.02%
Max EPS beat(2)36.46%
EPS beat(4)1
Avg EPS beat(4)-365.14%
Min EPS beat(4)-1032.86%
Max EPS beat(4)36.46%
EPS beat(8)2
Avg EPS beat(8)-208.81%
EPS beat(12)5
Avg EPS beat(12)-141.22%
EPS beat(16)9
Avg EPS beat(16)-103.51%
Revenue beat(2)1
Avg Revenue beat(2)-0.51%
Min Revenue beat(2)-5.19%
Max Revenue beat(2)4.16%
Revenue beat(4)1
Avg Revenue beat(4)-1.79%
Min Revenue beat(4)-6.04%
Max Revenue beat(4)4.16%
Revenue beat(8)4
Avg Revenue beat(8)0.21%
Revenue beat(12)6
Avg Revenue beat(12)-0.33%
Revenue beat(16)8
Avg Revenue beat(16)-0.03%
PT rev (1m)0.11%
PT rev (3m)4.53%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-43.12%
EPS NY rev (1m)4.18%
EPS NY rev (3m)-6.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.9%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)-0.69%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 288.55 | ||
| Fwd PE | 41.25 | ||
| P/S | 2.61 | ||
| P/FCF | 116.39 | ||
| P/OCF | 28.88 | ||
| P/B | 3.25 | ||
| P/tB | 31.57 | ||
| EV/EBITDA | 36.47 |
EPS(TTM)0.22
EY0.35%
EPS(NY)1.54
Fwd EY2.42%
FCF(TTM)0.55
FCFY0.86%
OCF(TTM)2.2
OCFY3.46%
SpS24.36
BVpS19.51
TBVpS2.01
PEG (NY)0.82
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.25% | ||
| ROE | -11.66% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 21.82% | ||
| FCFM | 2.24% |
ROA(3y)-2.82%
ROA(5y)-0.09%
ROE(3y)-8.14%
ROE(5y)-1.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.68%
GM growth 5Y-7.41%
F-Score5
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.38 | ||
| Debt/FCF | 49.84 | ||
| Debt/EBITDA | 11.05 | ||
| Cap/Depr | 61.22% | ||
| Cap/Sales | 6.78% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 90.27% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.51 | ||
| Quick Ratio | 1.93 | ||
| Altman-Z | 1.62 |
F-Score5
WACC9.31%
ROIC/WACCN/A
Cap/Depr(3y)125.99%
Cap/Depr(5y)159.79%
Cap/Sales(3y)11.57%
Cap/Sales(5y)13.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-61.4%
EPS 3Y-56.51%
EPS 5Y-33.48%
EPS Q2Q%-30%
EPS Next Y350.55%
EPS Next 2Y148.11%
EPS Next 3Y113.64%
EPS Next 5Y73.38%
Revenue 1Y (TTM)4.71%
Revenue growth 3Y3.1%
Revenue growth 5Y11.71%
Sales Q2Q%4.18%
Revenue Next Year8.33%
Revenue Next 2Y8.2%
Revenue Next 3Y8.33%
Revenue Next 5Y7.44%
EBIT growth 1Y-166.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year196.68%
EBIT Next 3Y58.17%
EBIT Next 5Y41.23%
FCF growth 1Y121.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y116.85%
OCF growth 3Y-14.78%
OCF growth 5Y1.59%